Abstract Background Advanced treatments for IBD typically have placebo-adjusted clinical remission rates of only 10 to 25%. The combined use of targeted biologic agents could break through this efficacy ceiling while avoiding the risks associated with broad immunosuppression. Spyre Therapeutics is developing fully human half-life extended IgG1 antibody drug candidates that can be used in combination against clinically validated IBD targets, including α4β7 integrin (SPY001) and TL1A (SPY002). The efficacy of combined inhibition of integrin β7 and TL1A was tested in proof-of-concept mouse colitis models. In advance of clinical assessment, it is essential to assess potential drug-drug effects on pharmacokinetics (PK). Accordingly, the clinical-stage antibodies SPY001 and SPY002 were evaluated in non-human primate (NHP) PK studies independently and in combination. Methods The efficacy of mouse surrogate anti-β7 or anti-TL1A antibodies used alone or in combination was assessed in the TNBS and anti-CD40 mouse models of colitis. Mice were treated with the antibodies or isotype control on Day -1 and Day 2. Body weight, stool consistency, blood in stool, and disease activity scores were recorded daily until the end of the study on Day 6. Colon weight and length were measured at the conclusion of the study. In separate experiments, SPY001 and SPY002 PK were measured in NHP following individual or combination dosing. Results In the murine TNBS model, combination therapy with anti-β7 and anti-TL1A antibodies significantly reduced body weight loss, improved body weight gain, and reduced disease activity to a greater extent than either monotherapy alone. In the anti-CD40 model, anti-β7 and anti-TL1A monotherapy increased weight gain and improved disease scores. Combination therapy reduced weight loss through Day 3, improved weight gain, improved disease activity, and reduced the colon weight-to-length ratio, all to a greater extent than either monotherapy. In NHPs, PK profiles of SPY001 and SPY002 were similar whether they were dosed individually or in combination. Conclusion Combined anti-β7 integrin and anti-TL1A therapy showed additive or greater than additive in vivo biological activity relative to either monotherapy in the TNBS and anti-CD40 mouse colitis models. Coadministration of SPY001 and SPY002 in NHPs demonstrated no drug-drug effects on PK. These preclinical results support the advancement of the combination of SPY001 and SPY002 into clinical trials.
Purpose The purpose of this paper is to tell the story of the evolution of knowledge exchange (KE) activity within a department in a university in the north west of England and to understand this activity through the lens of actor‐network theory. Design/methodology/approach Applying the sociology of translation to one qualitative interview shows how different actors were enrolled and mobilized into a KE actor‐network. The process of translation consists of four stages, problematisation, enrolment, interessement and mobilisation of allies which have been applied to the data to tell the story of the KE actor‐network. This is a cross‐disciplinary approach using a theoretical framework from sociology and applying it to a management/organizational context. Findings This framework brings fresh ways of looking at the importance of KE networks within universities. Although limited to one interview, the methodology allows for an in‐depth reading of the data and shows how resilient and flexible this actor‐network is to withstand and respond appropriately to shifts in policy and subsequent provisions for small‐ and medium‐sized enterprise business support. Originality/value Building from one case, the paper concludes that this account adds to an historical understanding of how universities become involved with KE activities. The inclusion of non‐human actors allows for a deeper understanding of the actor‐network and shows the importance of actors such as White Papers, pots of funding and physical buildings to the role of KE within higher education.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.